trending Market Intelligence /marketintelligence/en/news-insights/trending/kjrrnyybnm8tbupmyp8mnq2 content esgSubNav
In This List

Zymeworks licenses antibody platforms to Daiichi Sankyo

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Zymeworks licenses antibody platforms to Daiichi Sankyo

Canada's Zymeworks Inc. agreed to license two antibody platforms to Japan's Daiichi Sankyo Co. Ltd.

Under the agreement, Zymeworks will receive US$18 million up front for its Azymetric and Efect platforms, which enable the customization of certain antibody therapies. Daiichi Sankyo also agreed to pay up to US$466.7 million in milestone payments and double-digit tiered royalties on global product sales.

The agreement expands a 2016 cross-licensing and collaboration agreement between the companies.